Strive Health Partners with Nearly 200 Nephrology Providers Across Multiple States to Implement Innovative Medicare Kidney Care Program
Strive Health, a national innovator in value-based kidney care, today announced that it has partnered with nearly 200 physicians and advanced practitioners from 20 nephrology groups across several states to participate in Medicare’s Comprehensive Kidney Care Contracting options of the Kidney Care Choices model (CKCC).
CKCC is a new Center for Medicare and Medicaid Innovation (CMMI) payment innovation model that incentivizes healthcare providers to manage the care of Medicare beneficiaries with chronic kidney disease (CKD) stages 4 and 5 and end stage renal disease (ESRD). Unlike prior value-based kidney care models, CKCC addresses both CKD and ESRD beneficiaries and aligns patients based on nephrology care, not dialysis treatments. The implementation period for the program started on October 15, 2020 and the official launch of the performance period is on April 1, 2021.
“New payment models like CKCC are putting nephrologists at the center and creating meaningful opportunities to transform care for our patients,” said Gary Singer, MD, a nephrologist who leads Midwest Nephrology Associates in St. Louis, MO. “We looked for a partner whose incentives align with our goal of delaying the progression of kidney disease, and whose model blends technological innovation with high-touch care. We believe Strive is well-positioned to support us in CKCC and beyond.”
Strive Health provides technology, high-touch care teams, and management expertise that empower nephrologists to participate and succeed in new value-based kidney care models. Physicians partnering with Strive gain access to advanced tools and resources that improve care delivery, such as sophisticated data science models that predict CKD disease progression with greater than 95% accuracy. Physicians also participate in performance-based incentive programs that reward high-quality and low-cost patient outcomes.
“Our company is the market leader in transformative, value-based kidney care. The new CMMI models take an exciting step in the right direction and create unprecedented opportunities for nephrologists to innovate and be rewarded for high-quality, long-term care goals over individual treatments,” said Chris Riopelle, CEO and co-founder of Strive Health.
Through partnerships with nephrologists and direct care arrangements, Strive manages thousands of complex CKD and ESRD patients in five states today and will be managing, or supporting the management of, more than 30,000 patients in 12 states by early 2021. The company is actively launching new value-based kidney care arrangements with commercial payors, health systems, and medical groups – most recently announced include Humana and Conviva Health – and engaging local nephrologists as central care providers within these models. Future growth plans include new application opportunities for CKCC and additional government programs.
About Strive Health
Strive Health is a national innovator in value-based kidney care and partner of choice for leading healthcare payors and providers. Through a unique combination of high-touch care teams, advanced technology, seamless integration with local providers, and next-generation dialysis services, Strive deploys an integrated care delivery system that supports the entire patient journey from chronic kidney disease (CKD) to end stage renal disease (ESRD). Strive partners with commercial and Medicare Advantage payors, Medicare, health systems, and physicians through
Acute Ischaemic Stroke
A clot in the brain vessel of a stroke patient leads to instant death of brain tissue closest to the clot, shown in dark pink. The larger area surrounding the core (shaded) is characterised as the penumbra, tissue which can still be rescued.
MELBOURNE, Australia, Oct. 28, 2020 (GLOBE NEWSWIRE) — The drug afamelanotide will be used for the first time in patients with acute stroke. The study will evaluate the safety and efficacy of afamelanotide, developed by Australian company CLINUVEL, in arterial ischaemic stroke (AIS). The aim is to offer a treatment for patients suffering a stroke who are unable to receive treatment to dissolve or remove the underlying blood clot. AIS accounts for approximately 85% of the 15 million strokes suffered worldwide each year.
“Stroke is most commonly caused by a clot in a patient’s brain which starves surrounding tissue of blood and essential oxygen, causing the destruction of brain cells,” CLINUVEL’s Chief Scientific Officer, Dr Dennis Wright said. “This brain damage can have an irreversible effect on a patient’s ability to speak, move, and function, and tragically leads to an early death for more than 5.5 million people per annum. It is our aim to show that treatment with afamelanotide can safely reduce and prevent brain damage in the majority of stroke patients who cannot be offered standard therapy.”
Strokes cause death of brain tissue at the site of the clot and lead to a shortage of oxygen in a larger area of the brain, known as the penumbra, which is salvageable brain tissue if treated quickly. The longer the delay in a stroke patient receiving treatment, the greater the potential threat to their life and overall prognosis as tissue within the penumbra becomes irreversibly damaged.
Current stroke therapies rely on early intervention to restore blood flow to the brain by either chemically dissolving or physically removing the clot. In Europe, no treatment can be offered to over 85% AIS patients due to a critical delay between the start of the stroke and presentation of the patient to a hospital. Additionally, the location of the clot within the artery is also an important factor impacting the possibility to offer treatment.
Research has indicated that afamelanotide – which is approved in Europe and the USA for patients with a rare metabolic disorder called EPP1 – may rapidly exert its effects to protect brain tissue, act on blood vessels to optimise blood flow, and reduce the size of swelling in the brain following a stroke. More than 10,000 doses of afamelanotide have been administered to over 1,400 individuals during its development and use across a period of nearly two decades.
The pilot Phase IIa clinical study (CUV801) will be conducted
The United States Food and Drug Administration (FDA) has granted Abiomed (NASDAQ: ABMD) a 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 System™.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005299/en/
The Abiomed Breethe OXY-1 System has received 510(k) clearance from the United States FDA (Photo: Buisness Wire)
The ECMO system provides cardiopulmonary bypass support for patients whose lungs can no longer provide sufficient end organ oxygenation. The 510(k) clearance is to pump, oxygenate, and remove carbon dioxide from blood during cardiopulmonary bypass for up to six hours. The system can help provide oxygenation to patients suffering from cardiogenic shock or respiratory failure such as ARDS, H1N1, SARS, or COVID-19. When used with the Impella heart pump it can unload the heart and oxygenate the body, a combination therapy known as ECpella.
Abiomed’s Breethe technology is a novel, easy-to-use cardiopulmonary bypass system that is designed for mobility. The components of the system are designed to reduce the overall equipment footprint, support patient ambulation, and provide an intuitive interface for health care providers to setup and manage. The integrated pump lung unit is engineered with volute spiral technology for uniform blood flow with minimal stagnation and advanced gas exchange technology that allows for full therapy with reduced oxygen requirements.
“As a leader in technology and innovation, the Breethe system is a natural addition to Abiomed’s existing product portfolio,” said Michael R. Minogue, Abiomed’s Chairman, President and Chief Executive Officer. “This ECMO technology will allow us to support new patient populations, such as COVID-19 patients and others who need lung support, and provide combination ECpella therapy to Impella patients who need oxygenation. Furthermore, we will advance the field of native lung recovery and improve patient outcomes by collecting critical research data and developing and teaching best practices.”
“Abiomed has a long-established track record of bringing to market improved options to support physicians with innovative technology like Breethe, which is designed to provide advanced respiratory and cardiac support,” said Bartley Griffith, MD, the Hales Distinguished Professor of Surgery at University of Maryland, School of Medicine. “Abiomed is committed to advancing heart and lung therapies to help improve patient care and ultimately outcomes.”
“The clinical community has long been in need of innovation compared to traditional extracorporeal circulation therapy,” said Dr. Zachary Kon, cardiothoracic surgeon at New York University. “The Breethe system is a breakthrough technology because it supports transition from bed to ambulation via system portability. This system has the potential to revolutionize the way we think about extracorporeal life support therapy and can improve patient care.”
To help health care providers achieve the best possible outcomes, the Breethe system will be supported 24 hours a day, 7 days a week by Abiomed’s experienced field-based, in-hospital clinical team and on-call team from the Clinical Support Center.
This ECMO technology adds to Abiomed’s innovative portfolio focused on native heart and lung recovery. For many patients in cardiogenic shock, Abiomed now provides the treatment
Innovative Medicines Canada Responds to Release of Patented Medicine Prices Review Board’s (PMPRB) Final Guidelines
Press release content from Accesswire. The AP news staff was not involved in its creation.
OTTAWA, ON / ACCESSWIRE / October 23, 2020 / Innovative Medicines Canada (IMC) issued the following statement today in response to the release of PMPRB’s final Guidelines:
“For the last five years we have raised concerns about the negative impact PMPRB’s amendments to the Patented Medicines Guidelines and Regulations will have on Canadian patients. The final Guidelines released today do nothing to relieve those concerns.
“If implemented, they will have a negative impact on Canadian patients. Specifically, innovative new medicines will not launch in Canada, depriving patients of potentially life-changing new treatments; we will see further reductions in the number of clinical trials in this country; and our life sciences sector will lose out on critical investments.
“The height of a global public health crisis is the worst possible time to implement regulatory changes that will have such a direct and negative impact on Canadian patients. This is made even worse because the Guidelines released today are the result of an inadequate consultation process that largely ignored the significant concerns raised by industry, patients, researchers and others.
“Fortunately, there is still time to find a better path. Our members remain committed to their offer to work with government on a solution that meets their important public policy objectives, without undermining Canadians’ access to new medicines, or driving away investment.
“In the meantime, we will continue to ask that Health Canada delay the January 01, 2021 implementation of the final PMPRB Guidelines until after the COVID-19 crisis is passed. At this time our collective focus should only be on the discovery, development and delivery of COVID-19 medicines to treat those infected by the virus, and vaccines to halt its spread.”
About Innovative Medicines Canada
Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.
For further information:
SOURCE: Innovative Medicines Canada
View source version on accesswire.com: